New approaches to obesity treatment are emerging as scientists target underexplored metabolic pathways with the help of artificial intelligence. Demand for better obesity medicines is rising quickly, ...

CAMBRIDGE, Mass., Nov. 10, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research ...

At Web Summit Qatar, AI-powered biotech startups describe how automation, data, and gene editing are filling labor gaps in ...

Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intelligence drug development capabilities, offering up to $120 million to collaborate on small molecules for treating ...

CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage ...

Insilico nominates ISM3830, a potentially best-in-class, orally available and highly selective CBLB inhibitor with an AI‑empowered novel scaffold, as a preclinical candidate (PCC) for advanced tumor ...

Insilico Medicine has entered a multi-year research and development (R&D) collaboration with Servier, worth up to $888m, to develop and discover new oncology therapies. The partnership combines ...

Insilico Medicine, a U.S.-based, Hong Kong–listed AI drug discovery company, is launching a new service that will train general-purpose large language models, like OpenAI’s GPT or Alibaba’s Qwen, to ...

Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug ...

A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...

Artificial-intelligence-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibitor ...